10 June, 2016 · Overview

BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
For more information:
Company's web site at www.bindtherapeutics.com, and BANKRUPTCY OF NANOMEDICINE FIRM WORRIES DRUG DEVELOPERS (NATURE VOL 533, 19 MAY 2016 by Heidi Ledford) Read more